--- title: "Silo Pharma (SILO) news: reverse split and offering" url: "https://aibio.space/companies/silo-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SILO reverse split, offering, Nasdaq notice and merger news: Silo Pharma completes 1-for-15 reverse stock split. Silo Pharma, Inc." --- SILO Silo Pharma, Inc. NASDAQ · United States # Silo Pharma (SILO) news SILO reverse split, offering and Nasdaq notice news Financings · 2026-10-14 ## [Silo Pharma issues 150,000 shares to buy software and intellectual property](https://aibio.space/news/silo-pharma-issues-150-000-shares-buy-software-intellectual-property/) Silo Pharma agreed on October 13, 2026 to buy certain software and related intellectual property from Larry King in exchange for 150,000 shares of common stock. The shares are locked up for up to twelve months, and the 8-K names no underwriter or placement agent. ## Latest Silo Pharma news 1. 2026-10-02 Company Updates [Silo Pharma buys Norsight software assets for a warrant](https://aibio.space/news/silo-pharma-buys-norsight-software-assets-warrant/) Silo Pharma agreed on October 1, 2026, to acquire software, technology and intellectual property from Norsight Consulting in exchange for a warrant to buy 300,000 shares. 2. 2026-08-18 Company Updates [Silo Pharma issues 165,000 shares for software and domain names](https://aibio.space/news/silo-pharma-issues-165-000-shares-software-domain-names/) Silo agreed on August 18, 2026 to buy software, technology and domain names from Parkview Consulting LLC, paying with shares subject to a lock-up of up to twelve months. 3. 2026-07-10 Financings [Silo prices up to $11.7 million private placement](https://aibio.space/news/silo-prices-up-11-7-million-private-placement/) Silo agreed to sell 619,965 shares and warrants at $6.452 per share, with H.C. Wainwright & Co. as exclusive placement agent. The company expects about $4 million upfront. 4. 2026-06-18 Listings [Silo Pharma regains Nasdaq minimum bid price compliance](https://aibio.space/news/silo-pharma-regains-nasdaq-minimum-bid-price-compliance/) Nasdaq told Silo it regained compliance with the minimum closing bid price requirement as of June 17, 2026, and the matter is now closed. 5. 2026-06-01 Listings [Silo Pharma completes 1-for-15 reverse stock split](https://aibio.space/news/silo-pharma-completes-1-15-reverse-stock-split/) The Nevada certificate took effect on June 2, 2026, and shares began trading split-adjusted on Nasdaq on June 3. The ticker stays SILO under a new CUSIP number. 6. 2026-03-30 Company Updates [Silo issues 2,100,000 shares for QwikAgents software and domains](https://aibio.space/news/silo-issues-2-100-000-shares-qwikagents-software-domains/) Silo filed an 8-K covering an asset purchase from Many Ads Inc. paid for with 2,100,000 shares of common stock. The filing names no underwriter or placement agent. 7. 2025-12-29 Listings [Silo Pharma gets second 180 days from Nasdaq to meet $1.00 minimum bid price](https://aibio.space/news/silo-pharma-gets-second-180-days-nasdaq-meet-1-00-minimum-bid-price/) Silo Pharma did not regain the $1.00 minimum bid price by December 24, 2025, and Nasdaq granted it a second 180-day period to June 22, 2026. The company has told Nasdaq it may use a reverse stock split to cure the deficiency, and its annual report shows an accumulated deficit of $15,264,691. 8. 2025-07-03 Listings [Silo Pharma gets Nasdaq minimum bid price notice, has until December 24, 2025 to regain compliance](https://aibio.space/news/silo-pharma-gets-nasdaq-minimum-bid-price-notice-has-until-december-24/) Nasdaq notified Silo Pharma on June 27, 2025 that its common stock has not met the $1.00 minimum bid price. The company has until December 24, 2025 to regain compliance, and may consider a reverse stock split if needed. 9. 2025-07-03 Listings [Silo Pharma gets Nasdaq bid price notice, has until December 24, 2025](https://aibio.space/news/silo-pharma-gets-nasdaq-bid-price-notice-has-until-december-24-2025/) Nasdaq told Silo Pharma on June 27, 2025 that its common stock fell below the $1.00 minimum bid price, based on closing bids from May 14 to June 26. The company has until December 24, 2025 to regain compliance and says it may consider a reverse stock split. ## Silo Pharma at a glance - **Ticker**: SILO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $5.2 million ### Related companies - [Lotus Pharmaceuticals](https://aibio.space/companies/lotus-pharmaceuticals/) OTC: LTUS - [Lipocine](https://aibio.space/companies/lipocine/) NASDAQ: LPCN - [Aardvark Therapeutics](https://aibio.space/companies/aardvark-therapeutics/) NASDAQ: AARD - [Adicet Bio](https://aibio.space/companies/adicet-bio/) NASDAQ: ACET - [REGENXBIO](https://aibio.space/companies/regenxbio/) NASDAQ: RGNX - [AbbVie](https://aibio.space/companies/abbvie/) NYSE: ABBV - [Zomedica](https://aibio.space/companies/zomedica/) OTC: ZOMDF - [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) NASDAQ: TGTX ### Also on NASDAQ - [Gelteq](https://aibio.space/companies/gelteq/) GELS - [Beta Bionics](https://aibio.space/companies/beta-bionics/) BBNX - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) PVLA - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) TENX - [Champions Oncology](https://aibio.space/companies/champions-oncology/) CSBR - [Apnimed](https://aibio.space/companies/apnimed/) APMD ## What Silo Pharma does Silo Pharma, Inc. describes itself as a developmental stage biopharmaceutical and cryptocurrency company. Its therapeutics focus is on underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia and central nervous system diseases, using conventional drugs and psychedelic formulations. Its lead program, SPC-15, is an intranasal serotonin 4 (5-HT4) receptor agonist for PTSD and stress-induced anxiety disorders. The company holds an exclusive license agreement with Columbia University entered into July 1, 2024, and a license with Medspray Pharma BV for its soft mist nasal spray technology. It held a pre-IND meeting with the FDA in September 2024 and says it is aiming for an IND submission in 2026. SP-26 is a ketamine-based injectable dissolvable polymer implant for fibromyalgia and chronic pain and is in preclinical research. SPC-14 targets Alzheimer's disease, and SPU-16 is a CNS-homing peptide with initial research in multiple sclerosis; both are preclinical. The text also says the company plans to pursue rights to treat rare diseases. | Product or program | What it is | Stage | |---|---|---| | SPC-15 | Intranasal 5-HT4 receptor agonist for PTSD and stress-induced anxiety disorders | preclinical, IND-enabling studies | | SP-26 | Ketamine-based implant for fibromyalgia and chronic pain | preclinical research | | SPC-14 | Compound targeting glutamate and serotonin receptors for Alzheimer's disease | preclinical | | SPU-16 | CNS-homing peptide with initial research in multiple sclerosis | preclinical | Summarised from the company's [10-K filed Mar 27, 2026](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/ea0282804-10k_silo.htm). ## Silo Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$72,102](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/) | [$72,102](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/) | | Research and development | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/) | [$2.4 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/) | | Net income (loss) | [-$4.2 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/) | [-$4.4 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/) | | Cash from operations | [-$4.7 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/) | [-$3.8 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/) | | Cash and equivalents | [$4.7 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026089085/) | [$3.9 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/) | | Short-term investments | [$2.1 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026089085/) | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1514183/000121390026089085/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.3 million, plus short-term investments of $2.0 million, $5.2 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Silo Pharma Did Silo Pharma do a reverse stock split? Our latest story on this, dated Jun 1, 2026: "Silo Pharma completes 1-for-15 reverse stock split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/silo-pharma-completes-1-15-reverse-stock-split/). Has Silo Pharma raised money recently? Our latest story on this, dated Jul 10, 2026: "Silo prices up to $11.7 million private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/silo-prices-up-11-7-million-private-placement/). Has Silo Pharma received a Nasdaq deficiency notice? Our latest story on this, dated Dec 29, 2025: "Silo Pharma gets second 180 days from Nasdaq to meet $1.00 minimum bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/silo-pharma-gets-second-180-days-nasdaq-meet-1-00-minimum-bid-price/). Is Silo Pharma involved in a merger or acquisition? Our latest story on this, dated Oct 2, 2026: "Silo Pharma buys Norsight software assets for a warrant". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/silo-pharma-buys-norsight-software-assets-warrant/). What is the ticker symbol of Silo Pharma? Silo Pharma, Inc. trades under the ticker SILO on NASDAQ. Where is Silo Pharma listed? Silo Pharma, Inc. is listed on NASDAQ. What is the SEC CIK of Silo Pharma? The SEC Central Index Key (CIK) for Silo Pharma, Inc. is 1514183. Its filings are on SEC EDGAR. How many shares does Silo Pharma have outstanding? 1,588,250 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Silo Pharma listed under? Our directory records Silo Pharma, Inc. under United States. What does Silo Pharma do? Our directory classifies Silo Pharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Silo Pharma? The ISIN recorded for Silo Pharma, Inc. is US82711P3001. Does aibio.space cover Silo Pharma? aibio.space lists Silo Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Silo Pharma incorporated? SEC records list its state or country of incorporation as NV. What does Silo Pharma develop? Silo Pharma, Inc. describes itself as a developmental stage biopharmaceutical and cryptocurrency company. Its therapeutics focus is on underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia and central nervous system diseases, using conventional drugs and psychedelic formulations. What is SPC-15 from Silo Pharma? SPC-15: Intranasal 5-HT4 receptor agonist for PTSD and stress-induced anxiety disorders Stage: preclinical, IND-enabling studies. ## Investor discussion: Silo Pharma Members talk about Silo Pharma (SILO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Silo Pharma, newest first. Each line links the filing it comes from. 1. 2026-10-14 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390026109457/ea0308562-8k_silo.htm) 2. 2026-08-19 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390026091783/ea0302618-8k_silo.htm) 3. 2026-08-17 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390026090748/ea0302240-8k_silo.htm) 4. 2026-07-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390026077296/ea029760202ex99-1.htm) 5. 2026-06-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390026070212/ea029533901ex99-1.htm) 6. 2026-06-01 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390026063185/ea0292702-8k_silo.htm) 7. 2026-04-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/ea0284319-8k_silo.htm) 8. 2025-12-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390025125838/ea0271073-8k_silopharma.htm) 9. 2025-10-24 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390025102222/ea0262461-8k_silopharma.htm) 10. 2025-09-05 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390025085119/ea0255705-def14a_silo.htm) 11. 2025-08-25 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1514183/000207709625000053/ea0253999-pre14a_silo.htm) 12. 2025-07-29 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390025068740/ea0250629-8k_silo.htm) 13. 2025-07-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390025061531/ea0247862-8k_silo.htm) 14. 2025-04-25 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1514183/000121390025035652/ea0239454-s1_silo.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SILO on TradingView](https://www.tradingview.com/symbols/NASDAQ-SILO/). ## SEC filings and registration - **SEC name**: Silo Pharma, Inc. - **CIK**: 1514183 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SILO (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 677 N. WASHINGTON BLVD, SARASOTA, FL, 34236 - **Phone**: (718) 400-9031 - **Shares outstanding**: 1,588,250 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: Uppercut Brands, Inc.; Point Capital, Inc.; Gold Swap Inc ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1514183/000121390026109457/ea0308562-8k_silo.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1514183/000121390026106435/ea0307598-8k_silo.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1514183/000121390026091783/ea0302618-8k_silo.htm) filed 2026-08-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1514183/000121390026090748/ea0302240-8k_silo.htm) filed 2026-08-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1514183/000121390026089085/ea0301277-10q_silo.htm) filed 2026-08-13 - [S-3](https://www.sec.gov/Archives/edgar/data/1514183/000121390026081368/ea0298379-s3_silo.htm) filed 2026-07-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1514183/000121390026077296/ea0297602-8k_silo.htm) filed 2026-07-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1514183/000121390026073367/ea0296385-def14a_silo.htm) filed 2026-06-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001514183), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Silo Pharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SILO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Silo Pharma, Inc. - **Ticker**: SILO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US82711P3001 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SILO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/silo-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Silo Pharma (SILO) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/silo-pharma/